Get the Humana Stock Quote and Latest News Updates

To get the Humana stock quote, you can check the company's website or use a financial website like Yahoo Finance or Google Finance. These websites provide real-time stock quotes and updates.

Humana, Inc. is a health insurance company based in Louisville, Kentucky. It was founded in 1961 and has since grown to become one of the largest health insurance companies in the US.

To stay up-to-date on the latest news and updates about Humana, you can visit the company's investor relations page or sign up for their news alerts.

Humana is a company that provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell.

The company offers medical and supplemental benefit plans to individuals, including a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program.

Humana Inc. is a company that provides medical and specialty insurance products in the United States. It operates through two main segments: Insurance and CenterWell.

The company offers medical and supplemental benefit plans to individuals. These plans aim to provide comprehensive coverage for their healthcare needs.

Humana has a contract with the Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program. This program helps eligible individuals access affordable prescription medication.

The company also contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. These contracts enable Humana to offer a range of services to individuals in need.

Humana Inc. has a diverse team of Managers and Directors. James Rechtin is the CEO of the company, having taken over on June 30, 2024.

The Director of Finance and CFO, Celeste Brown, is 48 years old and has been in her role since January 10, 2025. Katherine Goodrich, on the other hand, is the Chief Tech/Sci/R&D Officer, although her age is not specified.

The Managers at Humana Inc. include Kurt Hilzinger, who is the Chairman and 64 years old. He has been in this position since December 31, 2013. Frank D'Amelio and Karen Katz are also Directors/Board Members, with ages 67 and 68 respectively. They have been in their roles since August 31, 2003 and September 22, 2019.

Here's a list of the Managers and Directors at Humana Inc.:

Humana's financials have been steadily increasing, with revenue reaching $106.37 billion in 2023, a 14.54% jump from the previous year. However, earnings took a hit, decreasing by 11.30% to $2.49 billion.

Their net sales have been projected to reach $117B in 2024, followed by $119B in 2025. Net income is expected to increase to $1.88B in 2024 and $2.99B in 2025. Net debt has been projected to decrease to $6.42B in 2024 and $6.11B in 2025.

Here are the projected financial figures for Humana in 2024 and 2025:

Humana's financial performance has been a mixed bag, with revenue growth but earnings decline. However, their projected financials look promising, with increasing net sales and net income.

Related reading: Cloudflare Stock Symbol

Humana's revenue has seen a significant increase, reaching $106.37 billion in 2023, a 14.54% jump from the previous year.

The company's financial performance is a mixed bag, with earnings decreasing by 11.30% in 2023.

Here's a breakdown of Humana's financial performance in recent years:

As you can see, Humana's revenue has been steadily increasing, while earnings have seen a slight decline in 2023, but have since recovered in 2024 and 2025.

Net income has also seen a significant increase, reaching $2.42 billion in 2024, a notable improvement from the previous year.

Humana's net debt has been steadily decreasing, reaching $5.32 billion in 2024, a 19.4% decrease from the previous year.

Revenue growth has been impressive, with a 11.3% year-over-year increase in 2024.

Insider activity is a key indicator of a company's financial health and potential future performance. Insider trading is a common practice where executives, directors, and other high-level employees buy or sell company shares.

Several insiders were involved in buying and selling shares in December 2024. O'Hara Michelle A. bought 7,061 shares on December 31, 2024.

The largest seller of shares was Diamond Susan M, who sold a total of 895 shares on December 14, 2024.

Other notable sellers include Agrawal Vishal, who sold 485 shares on the same day, and Renaudin George II, who sold 396 shares.

Here's a breakdown of the top sellers:

The buying activity was mostly done by Deshpande Samir, who bought a total of 708 shares on December 14, 2024.

If you're interested in Humana's dividend history, I've got some information for you. Their dividend calendar shows a steady increase in dividend payments over the years.

The highest dividend payment was $3.54 in 2023, with a yield of 0.77. This is significantly higher than the lowest payment of $0.00 in 2008, 2009, 2010, 2007, 2006, 2005, and 2004.

Here's a breakdown of Humana's dividend payments from 2011 to 2023:

Keep in mind that past performance is not a guarantee of future results, but it's good to know the trend.

Humana stock has seen some significant fluctuations in its market value over the past year. The current market capitalization is a whopping $35.85 billion.

The stock's previous close was at $294.63, and it has ranged from $212 to $403 throughout the year. This gives you an idea of the stock's volatility.

Here are some key performance indicators for Humana stock:

The stock's performance has been quite impressive, with a 17.36% increase in the current year. This is a significant jump, and it's essential to keep an eye on the stock's performance in the coming months.

Humana stock has been a topic of interest lately, and here are some recent updates that might be worth knowing.

Humana's price target has been adjusted by several analysts, including Wolfe Research, which raised it to $333 from $342, and Barclays, which adjusted it to $255 from $253. Piper Sandler also increased its price target to $288 from $270.

In other news, Humana has partnered with Mercy to increase access to primary care for patients 65 and older. This is a significant development that could have a positive impact on the company's stock performance.

Here are some key updates on Humana stock:

Humana's stock performance has also been influenced by analyst ratings and news. For example, Wells Fargo raised its price target to $337 from $315, and Truist Securities raised its price target to $290 from $260.

Humana Inc. has been making headlines recently with various updates and announcements. Wolfe Research adjusted their price target for Humana to $333 from $342, while maintaining an outperform rating.

Barclays also made a change, adjusting their price target to $255 from $253, but keeping their equalweight rating. This shows that different analysts have varying opinions on Humana's stock performance.

Mercy teams up with Humana to increase access to primary care for patients 65+, which is a positive development for the company. Piper Sandler adjusted their price target to $288 from $270, maintaining a neutral rating.

Wells Fargo raised their price target to $337 from $315, and maintained an overweight rating, causing Humana shares to rise. Truist Securities also raised their price target to $290 from $260, but maintained a hold rating.

Here is a summary of the recent analyst updates:

These updates show that Humana is receiving attention from various analysts, and their stock performance is being closely watched.

Humana's stock has been on a rollercoaster ride lately, falling over 30% due to rising healthcare utilization and CMS pushing back on insurer profits, impacting MA-focused companies.

Humana's Q3 earnings showed resilience despite these headwinds, indicating that the company is adapting to the changing landscape.

In fact, Wells Fargo recently raised Humana's price target to $337 from $315, maintaining an Overweight Rating, which suggests that some analysts believe the company's stock will perform well in the long run.

Wolfe Research also adjusted Humana's price target to $333 from $342, maintaining an Outperform Rating, echoing a similar sentiment.

Other analysts, like Piper Sandler, have adjusted their price targets for Humana, with some increasing and others decreasing, but all maintaining a Neutral or higher rating.

Here's a summary of recent price target adjustments for Humana:

These price target adjustments suggest that analysts are cautiously optimistic about Humana's future performance, despite the short-term challenges facing the company.